Early COVID-19 treatment trial for vulnerable cancer patients halted
NCT ID NCT04379518
Summary
This early-stage study tested whether two immune-stimulating drugs (rintatolimod and interferon) could help cancer patients fight off COVID-19 infections. The trial aimed to find safe doses and see if the treatment reduced the amount of virus in patients. It was designed for adults with cancer who had mild to moderate COVID-19 symptoms, but the study was terminated after enrolling only 4 people.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.